Internal Medicine News & Articles

1 Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy International Journal of Urology, April 11, 2013
Yoshimura K et al. - Authors review data from completed clinical trials of vaccine therapy, and discuss future trials to assess the current knowledge and future role of vaccine therapy for renal cell carcinoma in the era of recently developed targeted therapy. renal cell carcinoma is the most common malignant tumor originating from the kidney. Compared with other solid tumors, it does not respond to traditional management modalities, such as chemotherapy and ...

2 Renal cell carcinoma with areas mimicking renal angiomyoadenomatous tumor/clear cell papillary renal cell carcinoma Human Pathology, March 11, 2013
Petersson F et al. - The authors present a cohort of 8 renal carcinomas that displayed a variable light microscopic appearance of renal angiomyoadenomatous tumor/clear cell papillary renal cell carcinoma without fulfilling the criteria for these tumors. Despite the combination of positivity for (alpha)-methylacyl-CoA racemase and cytokeratin 7 in 2 cases, there was nothing to suggest of the possibility of a conventional papillary renal cell carcinoma with a predominance of ...

3 BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms Tumor Biology, March 21, 2013
Ehsani L et al. - The distinction between renal oncocytoma and renal cell carcinoma, especially chromophobe renal cell carcinoma and clear cell carcinoma with oncocytic features, is important due to the different biologic potentials of these tumors. This is the first study to date evaluating the expression of BCA2 in renal oncocytoma. BCA2 could serve as a marker that may be utilized in the distinction between renal oncocytoma and its mimickers.

4 Dietary supplement hymecromone and sorafenib: A novel combination for the control of renal cell carcinoma The Journal of Urology, June 14, 2013
Benitez A et al. - Authors recently noted that the hyaluronic acid receptors CD44 and RHAMM are potential predictors of metastatic renal cell carcinoma. In the current study they examined the antitumor properties of hymecromone, sorafenib and the combination in renal cell carcinoma models. This is the first study to show that the combination of sorafenib and the nontoxic dietary supplement hymecromone is highly effective for controlling renal cell carcinoma. Methods Using ...

5 Association of Thyroid, Breast and Renal Cell Cancer: A Population-based Study of the Prevalence of Second Malignancies Annals of Surgical Oncology, March 25, 2013
Van Fossen V.L.et al.-The purpose of this study was to evaluate the prevalence of a second malignancy in patients treated for thyroid, breast or renal cell cancer and determine what associations, if any, exist between these cancers.Analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results data has shown that the incidence of thyroid cancer is higher in patients with a preexisting malignancy and that the incidence of other malignancies is higher in patients ...

6 Recent advances in the treatment of metastatic renal cell carcinoma International Journal of Urology, May 24, 2013
Abe H et al. - Authors describe some of these new therapies, including the anti-vascular endothelial growth factor monoclonal antibody bevacizumab, several receptor tyrosine kinase inhibitors (sorafenib, sunitinib, pazopanib, axitinib, and tivozanib), the mammalian target of rapamycin inhibitors temsirolimus and everolimus, and new immunotherapy modalities, such as anti-cytotoxic T-lymphocyte-associated antigen 4 antibody and anti-programmed cell death ...

7 Gender differences in benign renal masses World Journal of Urology, March 1, 2013
Mauermann J et al. - This study aimed to examine gender-specific differences in benign renal tumors. This study demonstrated several gender-specific differences in benign renal tumors, especially in the histological types. Despite this, clinical–pathological features and management of benign renal tumors in men and women appear more alike than different. Methods This retrospective study included 135 adult Caucasian patients with 143 benign renal tumors, which were ...

8 A possible role for microrna-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance The Journal of Urology, April 25, 2013
Berkers J et al. - Authors identified microRNA driven mechanisms in clear cell renal cell carcinoma associated with the tumor response to the multitargeted receptor tyrosine kinase inhibitor sunitinib. In this study microRNA-141 down-regulation driven epithelial-to-mesenchymal transition in clear cell renal cell carcinoma was linked to an unfavorable response to sunitinib therapy. Reintroduction of microRNA-141 in vitro led to ...

9 Renal cell neoplasm of oncocytosis: a type of unclassified renal cell carcinoma Clinical and Experimental Nephrology Case Reports, April 24, 2013
Shinohara M et al. - A 69-year-old woman was referred to us because a cyst in the lower pole of the left kidney had been pointed out on screening ultrasound. Computed tomography (CT) demonstrated a mural nodule of the wall of the cyst with an enhancement effect, suggesting cystic renal cell carcinoma (cT1aN0M0). The patient underwent retroperitoneoscopic non-ischemic partial nephrectomy using a microwave tissue coagulator. A hematoxylin–eosin-stained specimen ...

10 Differential Diagnosis of Renal Tumors With Clear Cytoplasm: Clinical Relevance of Renal Tumor Subclassification in the Era of Targeted Therapies and Personalized Medicine Archives of Pathology & Laboratory Medicine, April 2, 2013
Goyal R et al. - The objective of this study is to highlight morphologic mimics of clear cell renal cell carcinoma and provide strategies to help differentiate clear cell renal cell carcinoma from other renal tumors and lesions. In challenging cases, submission of additional tissue is often an inexpensive and effective way to facilitate a correct diagnosis. If immunohistochemical stains are to be used, it is best to use a panel of markers, as no one marker is specific for a given renal ...